Elite Pharmaceuticals Inc (ELTP) stock
ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)
Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –
Elite Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Elite Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.10M, down 18.4% year over year. For fiscal 2026 it was $5.74M, down 27.9% from the year before. Over ten years it grew -7.4% a year on average. The highest annual figure on record is $14.73M in fiscal 2015.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $5.74M | -27.9% |
| FY2025 | Mar 31, 2025 | $7.96M | +15.7% |
| FY2024 | Mar 31, 2024 | $6.88M | +11.0% |
| FY2023 | Mar 31, 2023 | $6.20M | +53.0% |
| FY2022 | Mar 31, 2022 | $4.05M | -20.8% |
| FY2021 | Mar 31, 2021 | $5.11M | -7.6% |
| FY2020 | Mar 31, 2020 | $5.53M | -27.2% |
| FY2019 | Mar 31, 2019 | $7.60M | -21.0% |
| FY2018 | Mar 31, 2018 | $9.62M | +15.9% |
| FY2017 | Mar 31, 2017 | $8.30M | -33.2% |
| FY2016 | Mar 31, 2016 | $12.43M | -15.6% |
| FY2015 | Mar 31, 2015 | $14.73M | +272.0% |
| FY2014 | Mar 31, 2014 | $3.96M | +306.0% |
| FY2013 | Mar 31, 2013 | $975.25K | -43.8% |
| FY2012 | Mar 31, 2012 | $1.74M | +25.3% |
| FY2011 | Mar 31, 2011 | $1.39M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $2.03M | +21.3% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $1.64M | -19.6% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $1.04M | -42.0% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $1.39M | -29.5% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $1.67M | -22.6% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $2.04M | +18.8% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $1.79M | +27.8% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $1.97M | -24.9% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $2.16M | +89.2% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $1.72M | -29.2% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $1.40M | -2.7% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $2.62M | +113.3% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $1.14M | +19.7% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $2.43M | +228.2% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $1.44M | +50.9% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $1.23M | +9.9% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $955.44K | -20.5% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $738.81K | -58.4% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $956.63K | -23.2% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $1.12M | -2.7% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $1.20M | +27.4% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $1.78M | -29.0% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $1.25M | +26.2% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $1.15M | +80.0% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $943.88K | -33.0% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $2.50M | +83.3% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $986.83K | -59.8% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $637.49K | -74.0% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $1.41M | +6.1% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $1.36M | -57.7% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $2.45M | +7.2% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $2.46M | +7.4% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $1.33M | -32.5% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $3.22M | -19.2% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $2.29M | +50.0% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $2.29M | +80.5% |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $1.97M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $3.99M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $1.53M | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | $1.27M | – |
See a number that looks wrong?